<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558333</url>
  </required_header>
  <id_info>
    <org_study_id>CLAD</org_study_id>
    <nct_id>NCT04558333</nct_id>
  </id_info>
  <brief_title>CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation</brief_title>
  <official_title>CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung transplantation is the ultimate treatment for end stage lung diseases. Survival after&#xD;
      lung transplantation is limited mainly due to the development of chronic allograft&#xD;
      dysfunction (CLAD). Both acute cellular rejection and primary grade dysfunction (PGD) have&#xD;
      been associated with the development of CLAD. In this study we will investigate multiple&#xD;
      prognostic factors that influence long term survival after lung transplantation with a&#xD;
      specific interest in PGD, acute rejection and the development of CLAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At specific time points (according to protocol) exhaled breath, blood specimens,&#xD;
      bronchoalveolar lavage and biopsies will be collected. These will be analyzed in an attempt&#xD;
      to identify possible biomarkers that will predict the development of PGD and/or CLAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">October 2039</completion_date>
  <primary_completion_date type="Anticipated">October 2039</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>identify prognostic biomarkers in blood, bronchoalveolar lavage and exhaled breath that will determine long term survival after human lung transplantation.</measure>
    <time_frame>up to 520 weeks</time_frame>
    <description>death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives are obtaining information on the development of (Primary graft development) PGD in relationship to respiratory viruses, genetic profile and exhaled breath in patients and (if possible donors) after human lung transplantation.</measure>
    <time_frame>from transplantation till 72 hours after surgery</time_frame>
    <description>PGD</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Transplant Failure and Rejection</condition>
  <condition>Primary Graft Dysfunction</condition>
  <arm_group>
    <arm_group_label>LTx (lung transplant) patients</arm_group_label>
    <description>identification of possible biomarkers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood and exhaled breath specimens</intervention_name>
    <description>identification of possible biomarkers</description>
    <arm_group_label>LTx (lung transplant) patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      the first 72 hours after transplantation cell free DNA will be collected&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        all lung transplant recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all lung transplant recipients &gt; 18 years signed ICF (informed consent form)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna M Kwakkel-van Erp, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna M Kwakkel-van Erp, MD, PhD</last_name>
    <phone>38215469</phone>
    <phone_ext>+32</phone_ext>
    <email>johanna.Kwakkel-vanErp@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annemie Hufkens, Msc</last_name>
    <phone>38214142</phone>
    <phone_ext>+32</phone_ext>
    <email>annemie.Hufkens@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna M Kwakkel-van Erp, MD, PhD</last_name>
      <phone>38215469</phone>
      <phone_ext>+32</phone_ext>
      <email>johanna.Kwakkel-vanErp@uza.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Johanna Kwakkel - Van Erp</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Graft Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

